虽然单胺类药是抗抑郁药物的策略，但是新的发展方向是靶向谷氨酸神经递质系

Although monoamines are a strategy for antidepressants, the new development direction is drugs targeting the glutamate neurotransmitter system and combined drugs. GLYX-13 is a threonine-proline-proline-threonine polypeptide that can bind to the glycine site of the N-methyl-D-aspartate (NMDA) receptor to improve learning and memory in mice Ability [3, 4], but its mechanism of action is unclear. The GLYX-13 analog is O-tert-butyl-L-threonine-L-thiazolidine acid-L-proline-L-threonine amide.

Although monoamines are a strategy for antidepressants, the new direction of development is drugs and combination drugs that target the glutamate neurotransmitter system. GLYX-13 is susine-proline-proline-proline-susine polypeptides, which can be combined with N-methyl-D-dayolyine (NMDA) receptor glycine sites to improve learning and memory in mice, but its mechanism of action is not clear. The GLYX-13 analogue is O-Schbutyl-L-susine-L-pyridine-L-proline-L-sulamide.

Although monoamines are the strategy of antidepressant drugs, the new development direction is the drugs targeting glutamate neurotransmitter system and the combination of drugs. Glyx-13 is a threonine proline proline threonine polypeptide, which can bind to glycine site of N-methyl-D-aspartate (NMDA) receptor and improve learning and memory ability of mice [3,4], but its mechanism is still unclear. Glyx-13 analogue is o-tert-butyl-l-threonine-l-thiazolidinic acid-l-proline-l-threonine amide.<br>